Skip to content

Search

Group A streptococcal vaccines: Paving a path for accelerated development

Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.

Progress toward a global Group A streptococcal vaccine

The desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.

The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (2nd edition)

Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) occur at very high rates among Aboriginal and Torres Strait Islander people.

Group A Streptococcal Diseases and Their Global Burden

We review GAS transmission characteristics and prevention strategies, historical and geographical trends and report on the estimated global burden disease...

A national prospective surveillance study of acute rheumatic fever in Australian children

Acute rheumatic fever (ARF) is an important cause of heart disease in Indigenous people of northern and central Australia.

Rheumatic Fever Follow-Up Study (RhFFUS) protocol: A cohort study investigating the significance of minor

In Australia, rheumatic heart disease (RHD) is almost exclusively restricted to Aboriginal Australian and Torres Strait Islander people with children being...

The future of acute rheumatic fever and rheumatic heart disease in Australia

Globally, ARF and RHD cause more than a quarter of a million deaths and substantial disability each year.

Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present consensus document aims to provide practical evidence-based information to support the implementation of effective preventive measures.

Penicillin Reactions in Patients With Severe Rheumatic Heart Disease: A Presidential Advisory From the American Heart Association

Jonathan Rosemary Carapetis AM Wyber AM MBBS FRACP FAFPHM PhD FAHMS MBChB MPH FRACGP PhD Co-Head, Strep A Translation; Co-Founder of REACH Senior

Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease

Rheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually. Echocardiographic screening detects rheumatic heart disease at an early, latent stage. Whether secondary antibiotic prophylaxis is effective in preventing progression of latent rheumatic heart disease is unknown.